Revised forecast
Fiscal year ending June 2026 · Full yearPrevious forecast published 8 August 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The functional materials development support services and bio-manufacturing support services are expected to exceed the original plan, but revenue from the life sciences research support services remains sluggish. The main factors are the delayed recovery of the U.S. business and the deferral to the following fiscal year of revenue recognition for several large domestic projects. Profit is also expected to decline due to the predominantly fixed-cost structure.
| Item | Details |
|---|---|
| Net Sales | ¥1,600 million → ¥1,420 million（-11.2%） |
| Operating profit | ¥300 million → ¥210 million（-30.0%） |
| Ordinary income | ¥300 million → ¥210 million（-30.0%） |
| Profit attributable to owners of the parent | ¥260 million → ¥200 million（-23.1%） |
| Net income per share | 45.68 yen and sen → 35.59 yen and sen |
| Fiscal Period Covered | Fiscal year ending June 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 8 August 2025 |
| Previous-period results | Revenue: ¥1,455 million; operating profit: ¥249 million; ordinary profit: ¥240 million; net income attributable to owners of the parent: ¥256 million; earnings per share: ¥43.67 (fiscal year ended June 2025) |
| Reason for the revision | The functional materials development support services and bio-manufacturing support services are expected to exceed the original plan, but revenue from the life sciences research support services remains sluggish. The main factors are the delayed recovery of the U.S. business and the deferral to the following fiscal year of revenue recognition for several large domestic projects. Profit is also expected to decline due to the predominantly fixed-cost structure. |
| Dividend forecast revision | No revision (unchanged from the disclosure made on 8 August 2025) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The functional materials development support services and bio-manufacturing support services are expected to exceed plan, but revenue from the life sciences research support services has remained sluggish. The main factors are the delayed recovery of the U.S. business and the deferral to the following fiscal year of revenue recognition for several large domestic projects. Profit is also expected to decline due to the predominantly fixed-cost structure.